Several studies have shown a reduction in AMH in some childhood cancer survivors and following cancer treatment in adulthood,18,21,23,24,36–38 three studies have addressed the question of whether pretreatment AMH and other markers of the ovarian reserve can predict post-chemotherapy ovarian failure. Here, AMH is linked to ovarian dysfunction.